 Lisa Davis
Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 9 | 2018 | 1177 | 0.850 |
Why?
| | Antirheumatic Agents | 3 | 2018 | 308 | 0.450 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2013 | 35 | 0.380 |
Why?
| | Methotrexate | 2 | 2018 | 232 | 0.380 |
Why?
| | Rheumatology | 2 | 2020 | 133 | 0.320 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2010 | 80 | 0.310 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 141 | 0.290 |
Why?
| | Lipids | 1 | 2014 | 709 | 0.290 |
Why?
| | Workflow | 1 | 2010 | 184 | 0.280 |
Why?
| | Veterans Health | 3 | 2017 | 189 | 0.240 |
Why?
| | Cardiovascular Diseases | 4 | 2017 | 2185 | 0.230 |
Why?
| | Registries | 7 | 2017 | 2410 | 0.230 |
Why?
| | Ambulatory Care | 1 | 2010 | 608 | 0.220 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 590 | 0.220 |
Why?
| | Health Literacy | 2 | 2020 | 184 | 0.220 |
Why?
| | Decision Support Systems, Management | 2 | 2015 | 7 | 0.220 |
Why?
| | Severity of Illness Index | 6 | 2015 | 2945 | 0.210 |
Why?
| | Body Mass Index | 4 | 2017 | 2425 | 0.200 |
Why?
| | Time-to-Treatment | 1 | 2025 | 250 | 0.190 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2015 | 261 | 0.180 |
Why?
| | Stroke | 2 | 2025 | 1272 | 0.170 |
Why?
| | Osteoporosis | 2 | 2014 | 237 | 0.170 |
Why?
| | Glucocorticoids | 2 | 2015 | 531 | 0.160 |
Why?
| | Anticoagulants | 1 | 2025 | 750 | 0.150 |
Why?
| | Rheumatic Diseases | 1 | 2020 | 98 | 0.150 |
Why?
| | Atrial Fibrillation | 1 | 2025 | 558 | 0.140 |
Why?
| | Aged, 80 and over | 7 | 2025 | 8326 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 497 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 2146 | 0.120 |
Why?
| | Antiprotozoal Agents | 1 | 2015 | 15 | 0.110 |
Why?
| | Drug Repositioning | 1 | 2015 | 40 | 0.110 |
Why?
| | Toxoplasmosis | 1 | 2015 | 43 | 0.110 |
Why?
| | Toxoplasma | 1 | 2015 | 49 | 0.110 |
Why?
| | Genes, rel | 1 | 2014 | 4 | 0.110 |
Why?
| | Spondylarthritis | 1 | 2015 | 50 | 0.100 |
Why?
| | Time Factors | 5 | 2025 | 7171 | 0.100 |
Why?
| | Middle Aged | 11 | 2025 | 36176 | 0.100 |
Why?
| | Visual Analog Scale | 1 | 2013 | 34 | 0.100 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 119 | 0.100 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 99 | 0.100 |
Why?
| | Hand | 1 | 2015 | 161 | 0.100 |
Why?
| | Vascular Calcification | 1 | 2015 | 114 | 0.100 |
Why?
| | Aged | 11 | 2025 | 26125 | 0.100 |
Why?
| | Diphosphonates | 1 | 2014 | 68 | 0.100 |
Why?
| | Disability Evaluation | 1 | 2015 | 311 | 0.100 |
Why?
| | Spinal Fractures | 1 | 2014 | 76 | 0.100 |
Why?
| | Thrombectomy | 1 | 2013 | 79 | 0.100 |
Why?
| | Femoral Fractures | 1 | 2014 | 84 | 0.090 |
Why?
| | Symptom Assessment | 1 | 2013 | 136 | 0.090 |
Why?
| | Dyslipidemias | 1 | 2014 | 184 | 0.090 |
Why?
| | Pharmacists | 1 | 2015 | 259 | 0.090 |
Why?
| | Weight Loss | 1 | 2017 | 839 | 0.090 |
Why?
| | Obesity | 2 | 2017 | 3076 | 0.090 |
Why?
| | Triglycerides | 1 | 2014 | 518 | 0.090 |
Why?
| | Joints | 1 | 2013 | 107 | 0.090 |
Why?
| | Risk Factors | 6 | 2017 | 10874 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2015 | 5891 | 0.080 |
Why?
| | Male | 13 | 2025 | 72817 | 0.080 |
Why?
| | Brain Ischemia | 1 | 2013 | 360 | 0.080 |
Why?
| | Health Status | 1 | 2015 | 836 | 0.070 |
Why?
| | Hypertension | 1 | 2018 | 1273 | 0.070 |
Why?
| | Humans | 18 | 2025 | 145491 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2129 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 2 | 2015 | 1369 | 0.070 |
Why?
| | Cytokines | 1 | 2016 | 2054 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1058 | 0.070 |
Why?
| | Genotype | 1 | 2013 | 1853 | 0.070 |
Why?
| | Female | 11 | 2025 | 78763 | 0.070 |
Why?
| | Autoantibodies | 1 | 2015 | 1512 | 0.060 |
Why?
| | Research Design | 1 | 2013 | 1134 | 0.060 |
Why?
| | Neoplasms | 3 | 2017 | 2897 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1076 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 3 | 2016 | 775 | 0.060 |
Why?
| | Biomarkers | 2 | 2015 | 4283 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1216 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2355 | 0.060 |
Why?
| | Respiratory Tract Diseases | 2 | 2017 | 176 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2015 | 6070 | 0.050 |
Why?
| | Cause of Death | 2 | 2017 | 469 | 0.050 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 275 | 0.050 |
Why?
| | Veterans | 2 | 2014 | 1626 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2025 | 256 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 1332 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1544 | 0.050 |
Why?
| | Risk Assessment | 3 | 2017 | 3759 | 0.040 |
Why?
| | United States | 5 | 2017 | 16115 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2010 | 5426 | 0.040 |
Why?
| | Comorbidity | 2 | 2016 | 1659 | 0.040 |
Why?
| | Incidence | 2 | 2018 | 2915 | 0.040 |
Why?
| | Sex Factors | 2 | 2016 | 2110 | 0.040 |
Why?
| | Sulfasalazine | 1 | 2018 | 22 | 0.030 |
Why?
| | Adult | 4 | 2015 | 40707 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2950 | 0.030 |
Why?
| | Prospective Studies | 1 | 2010 | 8039 | 0.030 |
Why?
| | Hydroxychloroquine | 1 | 2018 | 65 | 0.030 |
Why?
| | Prednisone | 1 | 2018 | 221 | 0.030 |
Why?
| | Rheumatic Nodule | 1 | 2016 | 3 | 0.030 |
Why?
| | Prognosis | 2 | 2016 | 4323 | 0.030 |
Why?
| | Electronic Health Records | 2 | 2015 | 1187 | 0.030 |
Why?
| | Thinness | 1 | 2016 | 99 | 0.030 |
Why?
| | Atovaquone | 1 | 2015 | 4 | 0.030 |
Why?
| | Pyrimethamine | 1 | 2015 | 3 | 0.030 |
Why?
| | Parasitic Sensitivity Tests | 1 | 2015 | 3 | 0.030 |
Why?
| | Sulfadiazine | 1 | 2015 | 6 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 848 | 0.030 |
Why?
| | Clindamycin | 1 | 2015 | 14 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 218 | 0.030 |
Why?
| | Rheumatoid Factor | 1 | 2016 | 178 | 0.030 |
Why?
| | Macrolides | 1 | 2015 | 69 | 0.030 |
Why?
| | Lymphoma | 1 | 2016 | 234 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 94 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2015 | 150 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 478 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 208 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2016 | 422 | 0.030 |
Why?
| | Leukemia | 1 | 2016 | 246 | 0.030 |
Why?
| | Antipsychotic Agents | 1 | 2015 | 215 | 0.020 |
Why?
| | Causality | 1 | 2014 | 127 | 0.020 |
Why?
| | Life Style | 1 | 2016 | 483 | 0.020 |
Why?
| | Bone Density Conservation Agents | 1 | 2014 | 81 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 852 | 0.020 |
Why?
| | Health Services Research | 1 | 2015 | 392 | 0.020 |
Why?
| | Thrombolytic Therapy | 1 | 2013 | 166 | 0.020 |
Why?
| | Blood Pressure | 1 | 2018 | 1782 | 0.020 |
Why?
| | Fibrinolytic Agents | 1 | 2013 | 297 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1374 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 2093 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2130 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1468 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 978 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1896 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 928 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1816 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 2002 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1500 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2018 | 17269 | 0.020 |
Why?
| | Health Personnel | 1 | 2014 | 750 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3424 | 0.020 |
Why?
| | Age Factors | 1 | 2014 | 3340 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1953 | 0.010 |
Why?
| | Cohort Studies | 1 | 2014 | 5992 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2664 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 14192 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 22485 | 0.010 |
Why?
| | Animals | 1 | 2015 | 38141 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|